ICH M9 Draft [BE/BA News]

posted by Helmut Homepage – Vienna, Austria, 2018-07-16 14:49  – Posting: # 19065
Views: 735

Dear all,

on 27 June the ICH released the draft guideline

Biopharmaceutics Classification System-based Biowaivers (M9, step 2).

Public consultation is planned for August 2018 and adoption of the final guideline in May 2019.

I’m wondering how this guideline was developed where one of the founding members of ICH (Japan) does not accept BCS-based biowaivers at all… :confused:

Edit: Deadline for comments:
ANVISA, Brazil - Deadline for comments by 28 January 2019
EC, Europe - Deadline for comments by 6 February 2019
Health Canada, Canada - Deadline for comments by 4 November 2018
HSA, Singapore - Deadline for comments by 26 October 2018
MFDS, Republic of Korea- Deadline for comments by 31 December 2018
MHLW/PMDA, Japan - Deadline for comments by 29 January 2019
NMPA, China - Deadline for comments by 30 November 2018
Swissmedic, Switzerland - Refers to EC, Europe consultation
TFDA, Chinese Taipei - Deadline for comments by 31 October 2018

Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. ☼
Science Quotes

Complete thread:

 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
19,478 posts in 4,133 threads, 1,333 registered users;
online 7 (0 registered, 7 guests [including 4 identified bots]).
Forum time (Europe/Vienna): 05:14 CEST

If you don’t know anything about computers,
just remember that they are machines that do exactly what you tell them
but often surprise you in the result.    Richard Dawkins

BEBAC Ing. Helmut Schütz